Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Abstract

Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (10 days) and either baricitinib (14 days) or placebo (control).The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 11, 2020
Accession Number
AD1118396

Entities

People

  • Andre C Kalil
  • Aneesh K. Mehta
  • Angela R. Branche
  • Anne F. Luetkemeyer
  • Cameron R. Wolfe
  • Daniel A. Sweeney
  • David C. Lye
  • Guillermo M. Ruiz-palacios
  • Hana M. Sahly
  • Justino R. Pineda
  • Kay M. Tomashek
  • Lanny Hsieh
  • Mamta K. Jain
  • Nicole M. Iovine
  • Susan Kline
  • Thomas F. Patterson
  • Uriel Sandkovsky
  • Varduhi Ghazaryan
  • Victor Tapson
  • Vincent C Marconi

Organizations

  • University of Nebraska Medical Center

Tags

DTIC Thesaurus Topics

  • Airway Management
  • Birds
  • Covid-19
  • Embolism And Thrombosis
  • Ethnic Groups
  • Geographic Regions
  • Health
  • Health Care
  • Health Services
  • Hospitals
  • Infectious Diseases
  • Minority Groups
  • North America
  • Patient Care
  • Sars
  • United States

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Immunology and Pathology
  • Mental Health of Military Veterans with Posttraumatic Stress Disorder (PTSD): Risk Factors, Prevalence, Symptoms, and Treatment.